CD235a/GYPA Protein (AA 20-91) (Fc Tag)

Produktnummer ABIN7274765

Produktdetails

Target: CD235a/GYPA (GYPA) (Glycophorin A (GYPA))

Protein-Typ: Recombinant

Proteineigenschaft: AA 20-91

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses CD235a/GYPA Protein ist gelabelt mit Fc Tag.

Verwendungszweck: Human GPA Protein

Sequenz: Ser20-Glu91

Produktmerkmale: Recombinant Human GPA Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Ser20-Glu91.

Reinheit: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Sterilität: 0.22 μm filtered

Endotoxin-Niveau: Less than 1EU per μg by the LAL method.

Biological Activity Comment: The affinity constant of 1.16 μM as determined in SPR assay (Biacore T200). See testing image for detail.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: -20 to -80°C for 12 months as supplied from date of receipt., -80°C for 3-6 months after reconstitution., 2-8°C for 2-7 days after reconstitution., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Haltbarkeit: 12 months

Antigendetails

Target: CD235a/GYPA (GYPA) (Glycophorin A (GYPA))

Andere Bezeichnung: GPA (GYPA Produkte)

Synonyme: GYPA Protein, gpa Protein, AI853584 Protein, CD235a Protein, GPA Protein, GPErik Protein, GPSAT Protein, HGpMiV Protein, HGpMiXI Protein, HGpSta(C) Protein, MN Protein, MNS Protein, PAS-2 Protein, glycophorin A (MNS blood group) Protein, glycophorin A Protein, GYPA Protein, Gypa Protein

Hintergrund: Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.

Molekulargewicht: 34.7 kDa. Due to glycosylation, the protein migrates to 45-70 kDa based on Tris-Bis PAGE result.

Pathways: Maintenance of Protein Location